Official Title
Glucose Control In Hematopoetic Stem Cell Transplant
Phase
N/ALead Sponsor
University of OklahomaStudy Type
InterventionalStatus
Terminated Results PostedIndication/Condition
Hyperglycemia Hematopoietic Stem Cell TransplantationIntervention/Treatment
insulin human ...Study Participants
11To determine whether intensive glucose control results in improved mortality and reduced hospital stay length by performing a randomized trial of intensive glucose management (blood glucose goal 110 mg/dl) using continuous IV insulin and glucose vs. non-intensive glucose management (goal 200 mg/dl)
TO determine whether there are fewer infections, days without a fever, days on antibiotics given for an infection and time to marrow engraftment are improved by intensive glucose management; and to determine whether there is evidence of a reduction in measures of inflammation in patients randomized to intensive glucose management and whether reduction of inflammation is associated with outcome.
Use of sliding scale insulin as per Appendix 1
Automated insulin delivery system
Regular Sliding Scale Insulin administration for hyperglycemia
MiniMed Paradigm monitoring device for hyperglycemia
Inclusion Criteria: Patients older than 18 Must meet standard criteria for HSCT If patient is known diabetic at admit the may be maintained on home sulfonylurea and insulin if randomized to the conventional arm Exclusion Criteria: If on intensive arm patient must stop all oral hyperglycemic meds
| Event Type | Organ System | Event Term |
|---|
Outcome Measure Data Not Reported
Outcome Measure Data Not Reported
